Evidence map›Paper›PMID 25999785›Full record

ArticleInternational journal of biological sciences2015

The promyelocytic leukemia protein is upregulated in conditions of obesity and liver steatosis.

Arkaitz Carracedo, Déborah Rousseau, Nicholas Douris, Sonia Fernández-Ruiz, Natalia Martín-Martín, Dror Weiss, Kaitlyn Webster, Andrew C Adams, Mercedes Vazquez-Chantada, Maria L Martinez-Chantar and 5 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Arkaitz Carracedo1. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA ; 2. CIC bioGUNE, Bizkaia Technology Park, Derio, Spain ; 3. IKERBASQUE, Basque foundation for science, Bilbao, Spain ; 4. Biochemistry and Molecular Biology Department, University of the Basque Country (UPV/EHU), P. O. Box 644, E-48080 Bilbao, Spain.
Déborah Rousseau5. INSERM, U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France ; 6. University of Nice-Sophia-Antipolis, Faculty of Medecine, Nice, F-06107, Cedex 2, France.
Nicholas Douris7. Division of Endocrinology; Department of Medicine,Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA.
Sonia Fernández-Ruiz2. CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.
Natalia Martín-Martín2. CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.
Dror Weiss1. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Kaitlyn Webster1. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Andrew C Adams7. Division of Endocrinology; Department of Medicine,Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA ; 8. Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana, USA.
Mercedes Vazquez-Chantada2. CIC bioGUNE, Bizkaia Technology Park, Derio, Spain.
Maria L Martinez-Chantar2. CIC bioGUNE, Bizkaia Technology Park, Derio, Spain ; 9. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd).
Rodolphe Anty5. INSERM, U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France ; 6. University of Nice-Sophia-Antipolis, Faculty of Medecine, Nice, F-06107, Cedex 2, France ; 10. CHU of Nice, Digestive Center, Nice, F-06202, Cedex 3, France.
Albert Tran5. INSERM, U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France ; 6. University of Nice-Sophia-Antipolis, Faculty of Medecine, Nice, F-06107, Cedex 2, France ; 10. CHU of Nice, Digestive Center, Nice, F-06202, Cedex 3, France.
Eleftheria Maratos-Flier7. Division of Endocrinology; Department of Medicine,Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA 02215, USA.
Philippe Gual5. INSERM, U1065, Team 8, "Hepatic Complications in Obesity", Nice, F-06204, Cedex 3, France ; 6. University of Nice-Sophia-Antipolis, Faculty of Medecine, Nice, F-06107, Cedex 2, France.
Pier Paolo Pandolfi1. Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Funding

Targeting Tumor Suppressive Pathways for Cancer TherapyR35CA197529 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PANDOLFI, PIER PAOLO · 2015 to 2019
$4.6M
NCI NIH HHS R35 CA197529NIDDK NIH HHS 5T32DK751627
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Up-RegulationAdultAnimalsFatty LiverFemaleHumansLiverMaleMiceNuclear ProteinsObesityPromyelocytic Leukemia ProteinRNA, MessengerTranscription FactorsTumor Suppressor ProteinsNuclear ProteinsPML protein, humanPromyelocytic Leukemia ProteinRNA, MessengerTranscription FactorsTumor Suppressor Proteins

Identifiers

PMID25999785
PMCPMC4440252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.